Credit Suisse analyst Guy Hardwick reiterates Dover (NYSE:DOV) with a Outperform and maintains $174 price target.
FDA Lifts Clinical Hold On BioCryst’s BCX9930 Program For Rare Blood Disorder
The FDA lifted a partial clinical hold on BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) BCX9930 program. The company will resume enrollment under revised protocols…